Literature DB >> 9825841

Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation.

A Nagler1, A Bishara, C Brautbar, V Barak.   

Abstract

The dysregulation of cytokines is thought to play a role in the inflammatory and allospecific components of graft-versus-host disease (GVHD) and graft rejection (GR) post allogeneic bone marrow transplantation (BMT). Both complications occur post unrelated BMT at significantly higher frequencies than post BMT from identical sibling donors. The levels of tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-1beta, IL-6, IL-10 and IL-12 following unrelated BMT were measured to examine cytokine dysregulation involvement in GVHD and GR. Of the 26 patients included in this study, 15 developed GVHD (14 acute; 1 acute and chronic), 5 had GR and 6 had uneventful BMT. TNF-alpha was markedly elevated in 13/15 of the patients with GVHD and in 3/5 patients with GR. IL-6 was elevated in patients with acute GVHD and with GR. IL-12 levels were similar in pre- and post-BMT sera. No correlation was found between HLA-C match and cytokine levels. In conclusion, a positive correlation was found between elevated levels of TNF-alpha, IL-6 and IL-10, and GVHD (p < 0.05, p < 0.005 and p < 0.002 respectively) and GR (p < 0.01).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9825841

Source DB:  PubMed          Journal:  Cytokines Cell Mol Ther        ISSN: 1368-4736


  2 in total

1.  Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation.

Authors:  Menachem Bitan; Lola Weiss; Michael Zeira; Eyal Zcharia; Shimon Slavin; Arnon Nagler; Israel Vlodavsky
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

2.  Skeletal Muscle Dysfunction and Exercise Intolerance in Children Treated with Haematopoietic Stem Cell Transplant-A Pilot Feasibility Study.

Authors:  Sarah L West; Gillian White; Jessica E Caterini; Tammy Rayner; Tal Schechter; Paul C Nathan; Greg D Wells
Journal:  Int J Environ Res Public Health       Date:  2019-05-08       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.